What hurdles slow Covid-19 pill distribution to poorer nations?

Question

Accepted Answer

Hurdles Slowing Covid-19 Pill Distribution to Poorer Nations Identified

International health groups express concern that the distribution of Merck & Co's antiviral pill for Covid-19 could mirror the inequities observed in vaccine rollout, potentially disadvantaging nations with the most urgent needs. These concerns are amplified by the fact that Africa, for instance, has only achieved about 5% population immunization, underscoring a critical demand for effective therapeutics. While Merck applied for US emergency clearance of its molnupiravir pill on October 11th, following trial data showing a 50% reduction in hospitalizations and deaths, the path to equitable global access faces several challenges.
Regulatory and Production Capacity Concerns

Despite Merck's proactive step of licensing several generic manufacturers of molnupiravir before its own branded version gains authorization, international health officials believe these measures may not be sufficient to ensure adequate supply for low- and middle-income countries. Merck plans to produce 10 million treatment courses this year and 20 million next year, with licensing deals aimed at facilitating cheaper generic versions for 109 countries. However, the specific production plans of the eight chosen Indian drugmakers remain unclear, and manufacturing for low-income countries often necessitates World Health Organisation (WHO) approval, a process that can typically take months to complete.
Competition and Pricing Dynamics

Wealthier nations are actively securing supply deals, with the United States having already committed to acquiring 1.7 million courses and an option for an additional 3.5 million by January 2023, at a cost of approximately US$700 per course. This raises concerns that middle-income countries may struggle to negotiate effectively against richer nations for access to the medication. Experts suggest that relying solely on Merck's current licensing arrangements could lead to potential supply shortfalls and inflated pricing, creating a scenario where affluent countries outbid less affluent ones.
Global Organisational Inefficiencies

A report prepared for the UN’s Access to Covid-19 Tools Accelerator program highlights concerns that UN agencies are not acting with sufficient speed to secure adequate volumes of potential new treatments. This perceived lack of urgency among global organisations could further impede the timely distribution of crucial medicines. While Merck has stated its commitment to global access through tiered pricing and is exploring expanded licenses for generic molnupiravir to build sufficient global supply, the administrative and logistical complexities within international bodies pose a significant hurdle.

Reading history

Hide →

This history is cleared when the page is closed.

What hurdles slow Covid-19 pill distribution to poorer nations?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends